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Bronchiolitis obliterans (BO) is a disease with a poor prognosis,  and a key factor that limits long-term 
survival after allogeneic hematopoietic stem cell transplantation (HSCT).  We here report a case of a 
31-year woman with acute lymphatic leukemia,  which was treated by chemotherapy and HSCT,  and 
consequently developed BO 2 years after HSCT.  A non-tuberculous mycobacterial infection occurred 
and showed gradual exacerbation.  She started taking anti-mycobacterial drugs,  but lost appetite,  felt 
tired and ﬁnally lost consciousness one month after beginning medication.  Arterial blood gas revealed 
marked hypercapnia.  Using extracorporeal life support (ECLS),  the carbon dioxide concentration was 
reduced and her consciousness recovered.  To our knowledge,  this is the ﬁrst case in which ECLS was 
successfully used for hypercapnia in a patient with BO.
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ronchiolitis obliterans (BO) is the most common 
late noninfectious pulmonary complication fol-
lowing allogeneic hematopoietic stem cell transplanta-
tion (HSCT),  and is characterized by the onset of air 
ﬂow obstruction.  It was ﬁrst described following 
HSCT by Beschorner et al.  in 1978 [1],  who reported 
lymphocytic bronchitis in 10ｵ of autopsies from 
patients who died following HSCT.  In 1982,  Roca et 
al.  described fatal BO in a patient with a severe 
chronic GVHD following HSCT [2].  Since then,  
many reports have described this complication follow-
ing HSCT.  Recent data suggest that bronchiolitis 
obliterans syndrome may aﬀect up to 6ｵ of HSCT 
recipients and dramatically alters survival,  with 
overall survival of only 13ｵ at 5 years.  We report a 
case of a 31-year woman with BO after HSCT,  who 
presented with life-threatening hypercapnia and 
showed improvement under extracorporeal life sup-
port (ECLS),  which could be safely discontinued 
after 7 days.
Case Report
　 A 31-year woman with a history of acute lympho-
cytic leukemia (ALL) and who underwent chemother-
apy and HSCT was aﬀected with bronchitis obliterans 
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(BO) 2 years after HSCT.  She had become aware of 
an increase of sputum and dyspnea on exertion about 
one and a half years after HSCT.  A diagnosis of BO 
was made by the ﬁndings of a chest X-ray ﬁlm (Fig.  
1),  CT scan,  ventilation-ﬂow scintigraphy,  respira-
tory function test,  and clinical history.  She needed 
oxygen inhalation at a ﬂow of 5L/min through a nasal 
cannulas in the daytime and 4L/min with non-invasive 
positive pressure ventilation (NIPPV) at night.  The 
level of carbon dioxide was relatively stable around 
100mmHg.
　 She had other complications of pulmonary infection 
caused by the non-tuberculous mycobacterium (NTM) 
M. kansasii,  diabetes due to steroids,  and sinus tachy-
cardia.  She had also once experienced left pneu-
mothorax.  A month before admission to our hospital,  
antimycobacterial drugs,  including isoniazid (INH),  
rifampicin (RFP) and ethambutol (EB),  were given 
because of the mild aggravation of pulmonary M. 
kansasii infection.  She gradually lost appetite,  felt 
lazy and at last became unconscious.  Physical exami-
nation on admission revealed a temperature of 37.5℃,  
blood pressure 147/99mmHg,  pulse 124/min,  oxygen 
saturation 84ｵ (O2 4L/min with NIPPV),  and respi-
ratory frequency 25/min.  On auscultation,  breath 
sounds were hardly detected in both lungs,  and no 
systolic or diastolic murmurs were detected.  A chest 
X-ray ﬁlm revealed a small cavity with reticulonodular 
shadows around the right upper lung ﬁeld due to NTM 
infection newly occurred a month before admission 
(arrow).  There were no ﬁndings of exacerbation of BO 
itself or relapse of pneumothorax.  Arterial blood 
gases immediately after her transport to the intensive 
care unit (FiO2 100ｵ with NIPPV) were pH7.18,  
PaO2 236.8mmHg,  and PCO2 161.2mmHg.  Pulmonary 
function and head CT scan could not be assessed 
because of her severe condition.  Regarding laboratory 
ﬁndings,  renal and liver function tests were normal.  
On the basis of these ﬁndings,  the patient was diag-
nosed as having disturbance of consciousness with 
hypercapnia.
　 We ﬁrst tried to control respiration with NIPPV.  
Her oxygenation was well maintained with NIPPV,  
and the carbon dioxide density,  which had temporarily 
risen to 235mmHg,  gradually decreased to around 
150mmHg.  On the third day of hospitalization,  how-
ever,  the carbon dioxide density suddenly increased 
beyond 200mmHg and her consciousness got worse.  A 
chest X-ray ﬁlm showed no ﬁndings of new infection or 
pneumothorax.  We decided upon the additional use of 
ECLS to reduce carbon dioxide density without 
exchanging NIPPV for invasive ventilation,  because 
we wanted to avoid respiratory complications given the 
diagnosis of BO and her previous history of pneu-
mothorax.  ECLS was initiated via both femoral veins,  
the left femoral vein for blood transmission and right 
femoral vein for blood retransfusion,  16 Fr and 18 
Fr,  35 centimeters and 20 centimeters in length,  
respectively,  with a blood ﬂow of 1.5L/min,  sweep 
gas ﬂow 100ｵ O2 5L/min.
　 The carbon dioxide density,  which had increased to 
around 200mmHg at the beginning of ECLS,  gradu-
ally lowered.  Ten h later,  the level of carbon dioxide 
was 129mmHg,  acidosis had improved to pH7.278,  
and the patient was able to communicate.  The level of 
carbon dioxide was kept around 100mmHg with a 1.0-
1.5L/min ﬂow 3 days after adopting ECLS.  Blood 
transfusion was needed for progressive anemia.  
ECLS was discontinued a week later,  and no re-
increase of the carbon dioxide level was seen (Fig.  2).
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Fig. 1　 An X-ray ﬁlm of the chest just before admission showed 
overinﬂation of both lungs and a newly occurred small cavity in the 
right upper lung ﬁeld (arrow).  There were no ﬁndings of exacerba-
tion of BO itself or relapse of pneumothorax.
Discussion
　 The ECLS system,  ﬁrst used clinically by Phillips 
et al.  in 1983 [3],  is generally used to contribute to 
hemodynamic stabilization.  It is widely used for car-
diopulmonary resuscitation and is valued in emergency 
cases due to its easy and quick application [4-6].  It 
is also used in thoracic surgery such as sleeve pneu-
monectomy,  to assist ventilation [7-9].  In this report,  
we introduced successful ECLS for severe hypercap-
nia in a patient with BO.  One report exists in which 
ECLS was used on patients with hypercapnia and 
severe emphysema as a support during operation [10].  
To our knowledge,  however,  no case of hypercapnia 
with BO treated by ECLS has been previously 
reported.
　 BO is the most common late noninfectious pulmo-
nary complication following allogeneic HSCT,  charac-
terized by the onset of air ﬂow obstruction.  Patients 
with BO often develop hypercapnia through an imbal-
ance of the delicate respiratory dynamic state due to 
events such as infection or progression of BO itself.  
In our case,  the patient had taken antimycobacterial 
drugs (INH/RFP/EB) because of the exacerbation of 
pulmonary non-tuberculous mycobacteriosis a month 
before she presented with general fatigue and appetite 
loss,  well known as adverse eﬀects of RFP.  Suﬃcient 
examinations,  including CT scan and pulmonary func-
tion test,  could not be done because of her severe 
condition,  but a chest X-ray ﬁlm and clinical course 
showed no manifest progression of the BO itself.  We 
concluded that her disturbance of consciousness was 
reversibly induced by marked hypercapnia,  and 
decided to use ECLS with NIPPV.
　 No clear indications for the use of ECLS have been 
determined because there is no objective evaluation 
regarding the relationship between the use of ECLS 
and the severity of shock in patients with acute circu-
latory failure,  much less in patients with respiratory 
failure.  In our case,  the patient showed uncorrectable 
hypercapnia with pH＜7.1 under the use of NIPPV;  
further,  she was aﬀected with respiratory disease and 
had a previous history of pneumothorax.  These condi-
tions induced us to use ECLS to improve severe 
hypercapnia.  ECLS may be strongly indicated for 
treatment of hypercapnia if invasive mechanical venti-
lation is not recommended.  Hypercapnia that cannot 
be corrected by mechanical ventilation should also be 
considered as an indication for ECLS.
　 The patient achieved spontaneous and stable 
breathing after the correction of the carbon dioxide 
density and recovery of consciousness.  In our case,  
antimycobacterial drugs including RFP might have 
caused fatigue and resulted into hypercapnia,  and the 
cessation of these drugs improved the patientʼs condi-
tion,  with help from ECLS.
　 Using ECLS,  we experienced the progression of 
anemia,  which we could handle with blood transfusion.  
Other complications with ECLS include systemic 
thrombosis,  leg ischemia,  renal insuﬃciency,  or sys-
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Fig. 2　 The course of the patient during hospitalization.  Carbon dioxide density gradually reduced to the level she had had before 
admission,  and acidosis was corrected by the use of extracorporeal life support (ECLS).
temic inﬂammatory response,  but our patient did not 
have these complications because the ECLS duration 
was short.
　 In conclusion,  we successfully adopted an ECLS 
system for a patient with life-threatening hypercapnia 
due to severe BO.
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